Saprocan: Saracatinib (Azd0530) And Docetaxel In Metastatic,Castrate-Refractory Prostate Cancer (Mcrpc)-A Phase I/Randomized Phase Ii Study By The United Kingdom National Cancer Research Institute Prostate Group.

Robert J. Jones,Amit Bahl, Johann S. De Bono,Christy Ralph,Tony Elliott,Angus Robinson,Charlotte Westbury,Alison Jane Birtle,John Nicholas Staffurth, Andrew Protheroe,Balaji Venugopal,Fiona Thomson,Chantevy Pou,Karen Morris,Jonathan Tugwood, Laura Divers,Carol Hopkins,Elaine McCartney,Caroline Kelly,Simon J. Crabb

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览7

暂无评分

摘要

107Background: Saracatinib is an orally-available, highly selective inhibitor of Abl and Src family members. It is an ATP-competitive tyrosine kinase inhibitor. Preclinical data suggested that the ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要